TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01436331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+CBT for pts+Family Intervention+CM.
Description: The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
Study: NCT01995175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab sampling
Description: Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.

Intervention type: OTHER
Group type: OTHER
Intervention: Diary cards
Description: Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
Study: NCT02564445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants will be entered with their teammate into a game that includes points and levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants will be entered with their teammate into a game that includes points and levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share Data with PCP
Description: Weight and step count data will be shared with the participant's primary care physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on weight
Description: Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on weight
Description: Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on weight
Description: Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on step counts
Description: Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on step counts
Description: Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on step counts
Description: Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
Study: NCT00723190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLONICEL (Clonidine HCl sustained release)
Description: 0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
Study: NCT02650947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of empty capsule everyday for 4 weeks
Study: NCT01741792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
Study: NCT01058759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Enoxaparin
Study: NCT03586479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive storybook reading
Description: Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive storybook reading
Description: Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive storybook reading
Description: Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
Study: NCT00467961

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Miltenyi system
Description: Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
Study: NCT00070018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 250 mg/m\^2, as part of Zevalin regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4000-5000 cGy total

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan
Description: 0.4 mCi/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium-111 ibritumomab tiuxetan
Description: 5 mCi
Study: NCT00928941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video game
Description: An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
Study: NCT04494763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: Non-selective Beta-blocker

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive drug
Study: NCT00767039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta (beractant)
Description: beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf (poractant)
Description: poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
Study: NCT03191136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
Study: NCT02782299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
Study: NCT01491750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GUIDED IMAGERY
Description: DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
Study: NCT01501773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell
Description: Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
Study: NCT03438734

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional cerebral oxygen saturation
Description: Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Regional cerebral oxygen saturation
Description: Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
Study: NCT00875433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: patients to receive continuous oral daily dosing of BIBW 2992
Study: NCT01765829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation antipsychotic treatment
Description: Dose reduction until withdrawal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic treatment
Description: Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
Study: NCT01397786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks
Study: NCT04048759

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personal Coach
Description: Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
Study: NCT01067625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOGA® System
Description: Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
Study: NCT03541330

Intervention type: OTHER
Group type: OTHER
Intervention: semi-directive interview
Description: semi-structured interview conducted by a clinical psychologist
Study: NCT00843037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
Study: NCT03500458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants will be asked to increase time in bed at least 1 hour more than baseline
Study: NCT02410083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopirin 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel-Aspirin(co-administration) 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopirin 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel-Aspirin(co-administration) 2
Study: NCT01310556

Intervention type: OTHER
Intervention: ogtt for patients with coronary artery disease
Description: 75 g OGTT
Study: NCT01222377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: Undergo endoscopic breast surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04631328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growing Together
Description: Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
Study: NCT00707876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 1 versus non-contrast MRA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 2 versus non-contrast MRA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 3 versus non-contrast MRA
Study: NCT02106416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study: NCT03203928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Intervention for Women with ADHD
Description: The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
Study: NCT03160001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50mg weekly
Study: NCT02237209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 Vaccine
Description: 10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study: NCT06011161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relationship Checkup (BRC)
Description: The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status.
Study: NCT04489381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered orally twice daily with food for 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study: NCT02982616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dodecanoic acid
Description: The middle chain saturated fatty acid that can be widely found in daily food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dodecanoic acid
Description: The middle chain saturated fatty acid that can be widely found in daily food.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive emotion
Description: Positive emotion induced by facial expressions and classic music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive emotion
Description: Positive emotion induced by facial expressions and classic music.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: saline
Description: saline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neutral emotion
Description: Neutral emotion induced by facial expressions and classic music.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: neutral emotion
Description: Neutral emotion induced by facial expressions and classic music.
Study: NCT02651415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
Study: NCT03551951

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for circulating tumor cells, DNA alterations

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for circulating tumor cells, DNA alterations
Study: NCT01980901

Intervention type: DEVICE
Intervention: Ovation™/Ovation Prime™ Abdominal Stent Graft System
Description: Single occurence permanent implant of AAA device.
Study: NCT01235975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MencevaxACWY TM
Description: Subcutaneous injection
Study: NCT00791921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
Study: NCT03551951

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for circulating tumor cells, DNA alterations
Study: NCT00791921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: Placebo given every 2 weeks until Week22 (SC)
Study: NCT06619470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binaural beats
Description: binaural beats

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: binaural beats
Description: binaural beats
Study: NCT04825821

Intervention type: PROCEDURE
Intervention: Clinical and ultrasonographic assessment
Description: Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures

Intervention type: PROCEDURE
Intervention: Clinical and ultrasonographic assessment
Description: Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures